

## Special Issue

# Diagnosis and Therapy in Urothelial Cancer

### Message from the Guest Editor

Urothelial cancer represents a constantly growing challenge in the urological scenario. Continuous diagnostic innovations, such as the introduction of new biomarkers, and therapeutic innovations with the use of new immunotherapeutic drugs or engineered target therapies in association with new robotic platforms have significantly improved the management of the disease. The aim of this Special Issue is to summarize the best and most innovative papers in the diagnostic and therapeutic field related to urothelial neoplasia.

#### Keywords

- urothelial cancer
- bladder cancer
- biomarkers
- robotic surgery
- immunotherapy
- upper tract urothelial carcinoma

---

### Guest Editor

Dr. Giuseppe Palermo

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

---

### Deadline for manuscript submissions

31 March 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/244233](https://mdpi.com/si/244233)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)